Beyond rockets and Starlink, SpaceX's IPO is driven by the capital needed for its most ambitious goal: a fleet of space-based AI data centers. This venture is too expensive for private markets, forcing the public offering despite Elon Musk's previous reservations about short-termist investors.

SpaceX's potential $1.75T valuation can't be justified by a traditional "sum-of-the-parts" analysis of its current businesses. The premium reflects a venture-style bet on unproven, future projects like Starship, essentially offering public investors a chance to act as late-stage VCs.

Upcoming tech IPOs like SpaceX's are being valued on their compelling, aspirational narratives rather than traditional metrics like discounted cash flow (DCF). This suggests a market shift where investors store value in powerful, science-fiction-like stories over fundamentals.

SpaceX is targeting a record-breaking $1.75T IPO valuation, possibly while unprofitable. The strategy isn't based on conventional metrics but on Elon Musk's ability to "defy financial gravity." It leverages his reputation and a vastly larger public market (vs. the Alibaba IPO era) to command a valuation driven by future promise over current financials.

Unlike typical software companies with incremental annual growth, companies like SpaceX operate on 5-7 year cycles. They tackle a huge technical challenge (e.g., Starship), harvest its value (e.g., global cellular), and then move to the next one (e.g., data centers in space). This model justifies valuations based on the probability of achieving the next leap.

SpaceX's upcoming IPO uses its highly profitable core space and telecom business, which generates $8B in EBITDA, to finance the capital-intensive and unproven xAI division. Investors are buying into the familiar Tesla model: funding future innovation with the cash flow of a dominant existing business.

Companies pursuing revolutionary technologies like autonomous driving (Waymo) or VR (Reality Labs) must endure over a decade of massive capital burn before profitability. This affirms venture capital's core role in funding these long-term, high-risk, high-reward endeavors.

The upcoming SpaceX IPO is poised to generate over $80 billion in combined gains for early venture investors. This outcome validates the strategy of large "mega-funds" making long-term, high-conviction bets on capital-intensive companies, challenging the narrative that such funds are too big to produce top-tier venture returns.

Unlike in tech where an IPO is often a liquidity event for early investors, a biotech IPO is an "entrance." It functions as a financing round to bring in public market capital needed for expensive late-stage trials. The true exit for investors is typically a future acquisition.